Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: Insomnia, Related Distress Among Cancer Caregivers
Interventions: Cognitive Behavioral Therapy for Insomnia (CBT-I), Acupuncture, questionnaires, Diurnal Cortisol; Behavioral · Procedure · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Irvine, California • New York, New York

Conditions: Healthy Volunteers
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Normal Volunteers
Interventions: MNTX tablet (Formulation 1), MNTX tablet (Formulation 2); Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Healthy Female Volunteer
Interventions: D-0502; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Lung Cancer, Small Cell
Interventions: topotecan; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Lebanon, New Hampshire • The Bronx, New York • Philadelphia, Pennsylvania + 3 more

Conditions: Type 1 Diabetes (T1D)
Interventions: Golimumab, Placebo (matching golimumab); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 44 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Herpes Simplex II
Interventions: 3% w/w SPL7013 Gel, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 24 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Post Operative Pain
Interventions: GRT6005, Morphine, Placebo; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Hepatitis C
Interventions: telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C, telaprevir Formulation D; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Chronic Spinal Cord Injury
Interventions: NVG-291, Placebo; Drug
Lead sponsor: NervGen Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 21
States / cities: Birmingham, Alabama • Pheonix, Arizona • Downey, California + 18 more

Conditions: Bacterial Infections, Wounds
Interventions: Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R), Placebo, complex gel formulation without Vancomycin; Drug
Lead sponsor: Robert S Berman MD; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Jupiter, Florida

Conditions: Healthy
Interventions: AZD9742, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 23 Years to 45 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Glendale, California

Conditions: Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nab-paclitaxel, Paclitaxel, Questionnaire Administration, Ramucirumab; Procedure · Other · Drug + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diabetes Mellitus Type 1
Interventions: iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon, Lilly glucagon, iLet infusion set, Contact Detach infusion set; Device · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV, Tuberculosis
Interventions: Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more

Conditions: HIV Infections
Interventions: Efavirenz, Lamivudine, Stavudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 18
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 14 more

Conditions: COVID-19
Interventions: Placebo, Remdesivir, Baricitinib; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 1,033 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more

Conditions: HIV Infections
Interventions: Cabotegravir IR Formulation (reference), Cabotegravir DT Formulation (test 1), Cabotegravir DT Formulation (test 2); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Bacterial Vaginosis
Interventions: Lactobacillus crispatus CTV-05, Metronidazole, Placebo; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Chicago, Illinois + 1 more

Conditions: Chronic Weight Management
Interventions: ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Myeloma
Interventions: Daratumumab, Pomalidomide, All-trans retinoic acid, Dexamethasone; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Healthy Volunteers
Interventions: Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg, CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions: NMN and TMG (Euexia), Nicotinamide Mononucleotide (NMN), Placebo; Dietary Supplement
Lead sponsor: Scott Silveira; Other
Eligibility: 60 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Glycogen Storage Disease Type III
Interventions: UX053, Placebo, Antipyretic, H2 Blocker, H1 Blocker; Biological · Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more

Search by objective public record fields.

Study of Cognitive Behavioral Therapy for Insomnia (CBT-I) and Acupuncture for Insomnia and Related Distress Among Cancer Caregivers

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

VivaGel™ in Healthy Young Women

Bunionectomy Trial With GRT6005

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury

Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM)

AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects

Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

LACTIN-V Study for Recurrent Bacterial Vaginosis

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)